Impact of rotavirus vaccination on rotavirus and all-cause gastroenteritis in peri-urban Kenyan children

Ernest Apondi Wandera, Shah Mohammad, Martin Bundi, Satoshi Komoto, James Nyangao, Cyrus Kathiiko, Erick Odoyo, Gabriel Miring'u, Koki Taniguchi, Yoshio Ichinose

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A monovalent rotavirus vaccine (RV1) was introduced into the National Immunization Program in Kenya in July 2014. We examined the impact of the vaccine on hospitalization for all-cause acute gastroenteritis (AGE) and rotavirus-specific AGE and strain distribution at a large referral hospital which serves a predominantly peri-urban population in Central Kenya. Data on rotavirus AGE and strain distribution were derived from ongoing hospital-based AGE surveillance. Hospital administrative data were used to compare trends in all-cause AGE. Pre-vaccine (July 2009–June 2014) and post-vaccine (July 2014–June 2016) periods were compared for changes in hospitalization for all-cause AGE and rotavirus AGE and strain distribution. Following the vaccine introduction, the proportion of children aged <5 years hospitalized for rotavirus declined by 30% (95% CI: 19–45%) in the first year and 64% (95% CI: 49–77%) in the second year. Reductions in rotavirus positivity were most pronounced among the vaccine-eligible group (<12 months) in the first year post-vaccination at 42% (95% CI: 28–56%). Greater reductions of 67% (95% CI: 51–79%) were seen in the second year in the 12–23 months age group. Similarly, hospitalizations for all-cause AGE among children <5 years of age decreased by 31% (95% CI: 24–40%) in the first year and 58% (95% CI: 49–67%) in the second year of vaccine introduction. Seasonal peaks of rotavirus and all-cause AGE were reduced substantially. There was an increased detection of G2P[4], G3P[6] and G3P[8], which coincided temporally with the timing of the vaccine introduction. Thus, introducing the rotavirus vaccine into the routine immunization program in Kenya has resulted in a notable decline in rotavirus and all-cause AGE hospitalizations in Central Kenya. This provides early evidence for public health policy makers in Kenya to support the sustained use of the rotavirus vaccine in routine immunizations.

Original languageEnglish
Pages (from-to)5217-5223
Number of pages7
JournalVaccine
Volume35
Issue number38
DOIs
Publication statusPublished - 12-09-2017

Fingerprint

Rotavirus
gastroenteritis
Gastroenteritis
Vaccination
vaccination
vaccines
Kenya
Vaccines
Rotavirus Vaccines
Hospitalization
Immunization Programs
immunization
health policy
urban population
Urban Population
public policy
Public Policy
Health Policy
Administrative Personnel
Immunization

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Wandera, E. A., Mohammad, S., Bundi, M., Komoto, S., Nyangao, J., Kathiiko, C., ... Ichinose, Y. (2017). Impact of rotavirus vaccination on rotavirus and all-cause gastroenteritis in peri-urban Kenyan children. Vaccine, 35(38), 5217-5223. https://doi.org/10.1016/j.vaccine.2017.07.096
Wandera, Ernest Apondi ; Mohammad, Shah ; Bundi, Martin ; Komoto, Satoshi ; Nyangao, James ; Kathiiko, Cyrus ; Odoyo, Erick ; Miring'u, Gabriel ; Taniguchi, Koki ; Ichinose, Yoshio. / Impact of rotavirus vaccination on rotavirus and all-cause gastroenteritis in peri-urban Kenyan children. In: Vaccine. 2017 ; Vol. 35, No. 38. pp. 5217-5223.
@article{4a39b381bbac4f418ba75aa01c3367f4,
title = "Impact of rotavirus vaccination on rotavirus and all-cause gastroenteritis in peri-urban Kenyan children",
abstract = "A monovalent rotavirus vaccine (RV1) was introduced into the National Immunization Program in Kenya in July 2014. We examined the impact of the vaccine on hospitalization for all-cause acute gastroenteritis (AGE) and rotavirus-specific AGE and strain distribution at a large referral hospital which serves a predominantly peri-urban population in Central Kenya. Data on rotavirus AGE and strain distribution were derived from ongoing hospital-based AGE surveillance. Hospital administrative data were used to compare trends in all-cause AGE. Pre-vaccine (July 2009–June 2014) and post-vaccine (July 2014–June 2016) periods were compared for changes in hospitalization for all-cause AGE and rotavirus AGE and strain distribution. Following the vaccine introduction, the proportion of children aged <5 years hospitalized for rotavirus declined by 30{\%} (95{\%} CI: 19–45{\%}) in the first year and 64{\%} (95{\%} CI: 49–77{\%}) in the second year. Reductions in rotavirus positivity were most pronounced among the vaccine-eligible group (<12 months) in the first year post-vaccination at 42{\%} (95{\%} CI: 28–56{\%}). Greater reductions of 67{\%} (95{\%} CI: 51–79{\%}) were seen in the second year in the 12–23 months age group. Similarly, hospitalizations for all-cause AGE among children <5 years of age decreased by 31{\%} (95{\%} CI: 24–40{\%}) in the first year and 58{\%} (95{\%} CI: 49–67{\%}) in the second year of vaccine introduction. Seasonal peaks of rotavirus and all-cause AGE were reduced substantially. There was an increased detection of G2P[4], G3P[6] and G3P[8], which coincided temporally with the timing of the vaccine introduction. Thus, introducing the rotavirus vaccine into the routine immunization program in Kenya has resulted in a notable decline in rotavirus and all-cause AGE hospitalizations in Central Kenya. This provides early evidence for public health policy makers in Kenya to support the sustained use of the rotavirus vaccine in routine immunizations.",
author = "Wandera, {Ernest Apondi} and Shah Mohammad and Martin Bundi and Satoshi Komoto and James Nyangao and Cyrus Kathiiko and Erick Odoyo and Gabriel Miring'u and Koki Taniguchi and Yoshio Ichinose",
year = "2017",
month = "9",
day = "12",
doi = "10.1016/j.vaccine.2017.07.096",
language = "English",
volume = "35",
pages = "5217--5223",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "38",

}

Wandera, EA, Mohammad, S, Bundi, M, Komoto, S, Nyangao, J, Kathiiko, C, Odoyo, E, Miring'u, G, Taniguchi, K & Ichinose, Y 2017, 'Impact of rotavirus vaccination on rotavirus and all-cause gastroenteritis in peri-urban Kenyan children', Vaccine, vol. 35, no. 38, pp. 5217-5223. https://doi.org/10.1016/j.vaccine.2017.07.096

Impact of rotavirus vaccination on rotavirus and all-cause gastroenteritis in peri-urban Kenyan children. / Wandera, Ernest Apondi; Mohammad, Shah; Bundi, Martin; Komoto, Satoshi; Nyangao, James; Kathiiko, Cyrus; Odoyo, Erick; Miring'u, Gabriel; Taniguchi, Koki; Ichinose, Yoshio.

In: Vaccine, Vol. 35, No. 38, 12.09.2017, p. 5217-5223.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of rotavirus vaccination on rotavirus and all-cause gastroenteritis in peri-urban Kenyan children

AU - Wandera, Ernest Apondi

AU - Mohammad, Shah

AU - Bundi, Martin

AU - Komoto, Satoshi

AU - Nyangao, James

AU - Kathiiko, Cyrus

AU - Odoyo, Erick

AU - Miring'u, Gabriel

AU - Taniguchi, Koki

AU - Ichinose, Yoshio

PY - 2017/9/12

Y1 - 2017/9/12

N2 - A monovalent rotavirus vaccine (RV1) was introduced into the National Immunization Program in Kenya in July 2014. We examined the impact of the vaccine on hospitalization for all-cause acute gastroenteritis (AGE) and rotavirus-specific AGE and strain distribution at a large referral hospital which serves a predominantly peri-urban population in Central Kenya. Data on rotavirus AGE and strain distribution were derived from ongoing hospital-based AGE surveillance. Hospital administrative data were used to compare trends in all-cause AGE. Pre-vaccine (July 2009–June 2014) and post-vaccine (July 2014–June 2016) periods were compared for changes in hospitalization for all-cause AGE and rotavirus AGE and strain distribution. Following the vaccine introduction, the proportion of children aged <5 years hospitalized for rotavirus declined by 30% (95% CI: 19–45%) in the first year and 64% (95% CI: 49–77%) in the second year. Reductions in rotavirus positivity were most pronounced among the vaccine-eligible group (<12 months) in the first year post-vaccination at 42% (95% CI: 28–56%). Greater reductions of 67% (95% CI: 51–79%) were seen in the second year in the 12–23 months age group. Similarly, hospitalizations for all-cause AGE among children <5 years of age decreased by 31% (95% CI: 24–40%) in the first year and 58% (95% CI: 49–67%) in the second year of vaccine introduction. Seasonal peaks of rotavirus and all-cause AGE were reduced substantially. There was an increased detection of G2P[4], G3P[6] and G3P[8], which coincided temporally with the timing of the vaccine introduction. Thus, introducing the rotavirus vaccine into the routine immunization program in Kenya has resulted in a notable decline in rotavirus and all-cause AGE hospitalizations in Central Kenya. This provides early evidence for public health policy makers in Kenya to support the sustained use of the rotavirus vaccine in routine immunizations.

AB - A monovalent rotavirus vaccine (RV1) was introduced into the National Immunization Program in Kenya in July 2014. We examined the impact of the vaccine on hospitalization for all-cause acute gastroenteritis (AGE) and rotavirus-specific AGE and strain distribution at a large referral hospital which serves a predominantly peri-urban population in Central Kenya. Data on rotavirus AGE and strain distribution were derived from ongoing hospital-based AGE surveillance. Hospital administrative data were used to compare trends in all-cause AGE. Pre-vaccine (July 2009–June 2014) and post-vaccine (July 2014–June 2016) periods were compared for changes in hospitalization for all-cause AGE and rotavirus AGE and strain distribution. Following the vaccine introduction, the proportion of children aged <5 years hospitalized for rotavirus declined by 30% (95% CI: 19–45%) in the first year and 64% (95% CI: 49–77%) in the second year. Reductions in rotavirus positivity were most pronounced among the vaccine-eligible group (<12 months) in the first year post-vaccination at 42% (95% CI: 28–56%). Greater reductions of 67% (95% CI: 51–79%) were seen in the second year in the 12–23 months age group. Similarly, hospitalizations for all-cause AGE among children <5 years of age decreased by 31% (95% CI: 24–40%) in the first year and 58% (95% CI: 49–67%) in the second year of vaccine introduction. Seasonal peaks of rotavirus and all-cause AGE were reduced substantially. There was an increased detection of G2P[4], G3P[6] and G3P[8], which coincided temporally with the timing of the vaccine introduction. Thus, introducing the rotavirus vaccine into the routine immunization program in Kenya has resulted in a notable decline in rotavirus and all-cause AGE hospitalizations in Central Kenya. This provides early evidence for public health policy makers in Kenya to support the sustained use of the rotavirus vaccine in routine immunizations.

UR - http://www.scopus.com/inward/record.url?scp=85026630809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026630809&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2017.07.096

DO - 10.1016/j.vaccine.2017.07.096

M3 - Article

C2 - 28780116

AN - SCOPUS:85026630809

VL - 35

SP - 5217

EP - 5223

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 38

ER -